Combined halp and GRIm scores for risk stratification in metastatic pancreatic ductal adenocarcinoma.

IF 3.1 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2026-09-12 DOI:10.1080/14796694.2026.2732589

Berkay Yeşilyurt, Ismet Seven, Fahriye Tuğba Köş

{"title":"Combined halp and GRIm scores for risk stratification in metastatic pancreatic ductal adenocarcinoma.","authors":"Berkay Yeşilyurt, Ismet Seven, Fahriye Tuğba Köş","doi":"10.1080/14796694.2026.2732589","DOIUrl":null,"url":null,"abstract":"Aims: Simple and accessible biomarkers are needed to improve prognostic assessment in metastatic pancreatic ductal adenocarcinoma (mPDAC). Immunonutritional indices derived from routine blood tests, such as the hemoglobin-albumin-lymphocyte-platelet (HALP) score and the Gustave Roussy Immune Score (GRIms), have shown prognostic relevance, but their combined and dynamic value remains unrevealed.Methods: We retrospectively evaluated 201 patients with mPDAC who received first-line chemotherapy between 2020 and 2024. Baseline and interval HALP and GRIms values were calculated using routine laboratory parameters. Associations with overall survival (OS) and progression-free survival (PFS) were assessed using Cox proportional hazards models.Results: Higher GRIms and lower HALP were associated with shorter OS and PFS (all p < 0.05). GRIms remained an independent prognostic factor in multivariable analyses. A combined HALP-GRIms score provided improved risk stratification and identified a subgroup with markedly reduced survival. Moreover, unfavorable changes in these scores during treatment were associated with poorer clinical outcomes.Conclusions: HALP and GRIms, particularly when evaluated in combination and over time, offer practical prognostic information in mPDAC. These findings support their role in baseline risk stratification and warrant further prospective validation.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-10"},"PeriodicalIF":3.1000,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2026.2732589","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Simple and accessible biomarkers are needed to improve prognostic assessment in metastatic pancreatic ductal adenocarcinoma (mPDAC). Immunonutritional indices derived from routine blood tests, such as the hemoglobin-albumin-lymphocyte-platelet (HALP) score and the Gustave Roussy Immune Score (GRIms), have shown prognostic relevance, but their combined and dynamic value remains unrevealed.

Methods: We retrospectively evaluated 201 patients with mPDAC who received first-line chemotherapy between 2020 and 2024. Baseline and interval HALP and GRIms values were calculated using routine laboratory parameters. Associations with overall survival (OS) and progression-free survival (PFS) were assessed using Cox proportional hazards models.

Results: Higher GRIms and lower HALP were associated with shorter OS and PFS (all p < 0.05). GRIms remained an independent prognostic factor in multivariable analyses. A combined HALP-GRIms score provided improved risk stratification and identified a subgroup with markedly reduced survival. Moreover, unfavorable changes in these scores during treatment were associated with poorer clinical outcomes.

Conclusions: HALP and GRIms, particularly when evaluated in combination and over time, offer practical prognostic information in mPDAC. These findings support their role in baseline risk stratification and warrant further prospective validation.

查看原文本刊更多论文

转移性胰腺导管腺癌风险分层的联合halp和GRIm评分。

目的：需要简单易懂的生物标志物来改善转移性胰腺导管腺癌（mPDAC）的预后评估。来自常规血液检查的免疫营养指标，如血红蛋白-白蛋白-淋巴细胞-血小板（HALP）评分和Gustave Roussy免疫评分（GRIms），已显示出预后相关性，但其综合和动态价值仍未揭示。方法：回顾性评估2020年至2024年间接受一线化疗的201例mPDAC患者。使用常规实验室参数计算基线和间隔期HALP和GRIms值。使用Cox比例风险模型评估与总生存期（OS）和无进展生存期（PFS）的关联。结果：较高的GRIms和较低的HALP与较短的OS和PFS相关（所有p）。结论：HALP和GRIms，特别是在联合评估和随时间推移时，为mPDAC提供了实用的预后信息。这些发现支持了它们在基线风险分层中的作用，并需要进一步的前瞻性验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.